FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207622> ?p ?o ?g. }

• W4387207622 endingPage "S1" @default.
• W4387207622 startingPage "S1" @default.
• W4387207622 abstract "Limited stage small-cell lung cancer (LS-SCLC) is associated with poor prognosis. We aimed to assess the efficacy and safety of high-dose, hyperfractionated thoracic radiotherapy of 54 Gy in 30 fractions compared with standard dose (45 Gy in 30 fractions) as a first-line treatment for LS-SCLC.The study was an open-label, randomized, phase 3 trial, done at 16 public hospitals in China. Key inclusion criteria were patients aged 18-70 years, with previously histologically or cytologically confirmed LS-SCLC, previously untreated or received 1-2 courses of intravenous cisplatin (75 mg/m²of body-surface area, on day 1 or divided into two days of each cycle) or carboplatin (area under the curve of 5 mg/mL per min, day 1 of each cycle)and intravenous etoposide (100 mg/m²of body-surface area, on days 1-3 of each cycle), and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.Eligible patients were randomly assigned (1:1) to receive volumetric-modulated arc radiotherapy (VMAT) of 45 Gy in 30 fractions or the simultaneous integrated boost VMAT (SIB-VMAT) of 54 Gy in 30 fractions to the primary lung tumor and lymph node metastases starting 0-42 days after the first chemotherapy course. Both groups of patients received thoracic radiotherapy twice per day and 10 fractions per week. Prophylactic cranial radiation (PCI, 25 Gy in 10 fractions) was implemented to patients with responsive disease. The primary endpoint was overall survival. Safety was analyzed in the as-treated population.Between June 30, 2017, and April 6, 2021, 224 eligible patients were enrolled and randomly assigned to 54 Gy (n = 108) or 45 Gy (n = 116). Median follow-up for the primary analysis was 45 months (IQR 41-48). Median overall survival was significantly improved in the 54 Gy group (62.4 months) compared with the 45 Gy group (43.1 months; p = 0.001). Median progression-free survival was significantly improved in the 54 Gy group (30.5 months) compared with the 45 Gy group (16.7 months; p = 0.044). The most common grade 3-4 adverse events were neutropenia (30 [28%] of 108 patients in the 54 Gy group vs 27 [23%] of 116 patients in the 45 Gy group), neutropenic infections (6 [6%] vs 2 [2%]), thrombocytopenia (13 [12%] vs 12 [10%]), anemia (6 [6%] vs 4 [3%]), and esophagitis (1 [1%] vs 3 [3%]). Treatment-related serious adverse events occurred in 9 [8%] patients in the 54 Gy group and 16 [14%] patients in the 45 Gy group. There were one treatment-related deaths in 54 Gy group (myocardial infarction).Compared with standard thoracic radiotherapy dose of 45 Gy, the high dose of 54 Gy improved overall survival and progression-free survival without increasing toxicities in patients with LS-SCLC, supporting twice-daily hyperfractionated thoracic radiotherapy of 54 Gy with concurrent chemotherapy is an alternative treatment option for LS-SCLC. This study is complete and registered with ClinicalTrials.gov, NCT03214003." @default.
• W4387207622 created "2023-09-30" @default.
• W4387207622 creator A5001729142 @default.
• W4387207622 creator A5004287650 @default.
• W4387207622 creator A5004402334 @default.
• W4387207622 creator A5009857183 @default.
• W4387207622 creator A5010104582 @default.
• W4387207622 creator A5013014678 @default.
• W4387207622 creator A5015195367 @default.
• W4387207622 creator A5017330670 @default.
• W4387207622 creator A5018447011 @default.
• W4387207622 creator A5022943551 @default.
• W4387207622 creator A5030169492 @default.
• W4387207622 creator A5039037784 @default.
• W4387207622 creator A5046387752 @default.
• W4387207622 creator A5046789634 @default.
• W4387207622 creator A5048995364 @default.
• W4387207622 creator A5049556592 @default.
• W4387207622 creator A5052444834 @default.
• W4387207622 creator A5053447705 @default.
• W4387207622 creator A5053915111 @default.
• W4387207622 creator A5054896880 @default.
• W4387207622 creator A5055526321 @default.
• W4387207622 creator A5060831159 @default.
• W4387207622 creator A5062120914 @default.
• W4387207622 creator A5064398610 @default.
• W4387207622 creator A5073436439 @default.
• W4387207622 creator A5079634371 @default.
• W4387207622 date "2023-10-01" @default.
• W4387207622 modified "2023-10-04" @default.
• W4387207622 title "High Dose Hyperfractionated Thoracic Radiotherapy vs. Standard Dose for Limited Stage Small-Cell Lung Cancer: A Multicenter, Open-Label Randomized, Phase 3 Trial" @default.
• W4387207622 doi "https://doi.org/10.1016/j.ijrobp.2023.06.205" @default.
• W4387207622 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784261" @default.
• W4387207622 hasPublicationYear "2023" @default.
• W4387207622 type Work @default.
• W4387207622 citedByCount "0" @default.
• W4387207622 crossrefType "journal-article" @default.
• W4387207622 hasAuthorship W4387207622A5001729142 @default.
• W4387207622 hasAuthorship W4387207622A5004287650 @default.
• W4387207622 hasAuthorship W4387207622A5004402334 @default.
• W4387207622 hasAuthorship W4387207622A5009857183 @default.
• W4387207622 hasAuthorship W4387207622A5010104582 @default.
• W4387207622 hasAuthorship W4387207622A5013014678 @default.
• W4387207622 hasAuthorship W4387207622A5015195367 @default.
• W4387207622 hasAuthorship W4387207622A5017330670 @default.
• W4387207622 hasAuthorship W4387207622A5018447011 @default.
• W4387207622 hasAuthorship W4387207622A5022943551 @default.
• W4387207622 hasAuthorship W4387207622A5030169492 @default.
• W4387207622 hasAuthorship W4387207622A5039037784 @default.
• W4387207622 hasAuthorship W4387207622A5046387752 @default.
• W4387207622 hasAuthorship W4387207622A5046789634 @default.
• W4387207622 hasAuthorship W4387207622A5048995364 @default.
• W4387207622 hasAuthorship W4387207622A5049556592 @default.
• W4387207622 hasAuthorship W4387207622A5052444834 @default.
• W4387207622 hasAuthorship W4387207622A5053447705 @default.
• W4387207622 hasAuthorship W4387207622A5053915111 @default.
• W4387207622 hasAuthorship W4387207622A5054896880 @default.
• W4387207622 hasAuthorship W4387207622A5055526321 @default.
• W4387207622 hasAuthorship W4387207622A5060831159 @default.
• W4387207622 hasAuthorship W4387207622A5062120914 @default.
• W4387207622 hasAuthorship W4387207622A5064398610 @default.
• W4387207622 hasAuthorship W4387207622A5073436439 @default.
• W4387207622 hasAuthorship W4387207622A5079634371 @default.
• W4387207622 hasConcept C126322002 @default.
• W4387207622 hasConcept C126894567 @default.
• W4387207622 hasConcept C155806632 @default.
• W4387207622 hasConcept C168563851 @default.
• W4387207622 hasConcept C203092338 @default.
• W4387207622 hasConcept C2776256026 @default.
• W4387207622 hasConcept C2776694085 @default.
• W4387207622 hasConcept C2778239845 @default.
• W4387207622 hasConcept C2779562246 @default.
• W4387207622 hasConcept C2780849966 @default.
• W4387207622 hasConcept C2781451048 @default.
• W4387207622 hasConcept C2908647359 @default.
• W4387207622 hasConcept C2989005 @default.
• W4387207622 hasConcept C45393284 @default.
• W4387207622 hasConcept C500558357 @default.
• W4387207622 hasConcept C509974204 @default.
• W4387207622 hasConcept C71924100 @default.
• W4387207622 hasConcept C99454951 @default.
• W4387207622 hasConceptScore W4387207622C126322002 @default.
• W4387207622 hasConceptScore W4387207622C126894567 @default.
• W4387207622 hasConceptScore W4387207622C155806632 @default.
• W4387207622 hasConceptScore W4387207622C168563851 @default.
• W4387207622 hasConceptScore W4387207622C203092338 @default.
• W4387207622 hasConceptScore W4387207622C2776256026 @default.
• W4387207622 hasConceptScore W4387207622C2776694085 @default.
• W4387207622 hasConceptScore W4387207622C2778239845 @default.
• W4387207622 hasConceptScore W4387207622C2779562246 @default.
• W4387207622 hasConceptScore W4387207622C2780849966 @default.
• W4387207622 hasConceptScore W4387207622C2781451048 @default.
• W4387207622 hasConceptScore W4387207622C2908647359 @default.
• W4387207622 hasConceptScore W4387207622C2989005 @default.
• W4387207622 hasConceptScore W4387207622C45393284 @default.
• W4387207622 hasConceptScore W4387207622C500558357 @default.
• W4387207622 hasConceptScore W4387207622C509974204 @default.
• W4387207622 hasConceptScore W4387207622C71924100 @default.

• next